New drug aims to tame autoimmune hepatitis and cut steroid use

NCT ID NCT07598825

Not yet recruiting Disease control Sponsor: Amgen Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This study tests a drug called inebilizumab in 180 adults with autoimmune hepatitis, a condition where the immune system attacks the liver. The goal is to see if the drug can reduce liver inflammation and allow patients to take lower doses of steroids. Participants will receive either inebilizumab or a placebo by IV, along with standard care, and be followed for safety and effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: inebilizumab (a drug given by IV infusion that targets immune cells)
What this could lead to: If it works, this could offer a new treatment option for people with autoimmune hepatitis, helping control the disease with less reliance on steroids.
What could go wrong: This is an early-stage trial (Phase 2/3) with only 180 participants. The drug may not prove effective or could have side effects. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AIH are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune hepatitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AIH AUTOIMMUNE HEPATITIS

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

American Research Corporation

San Antonio, Texas, 78215, United States
Amicis Research Center

Northridge, California, 91324, United States
Applied Research Center of Arkansas

Little Rock, Arkansas, 72205, United States
Beijing Friendship Hospital, Capital Medical University

Beijing, Beijing Municipality, 100050, China
Indiana University

Indianapolis, Indiana, 46202, United States
Inland Empire Liver Foundation

Rialto, California, 92377, United States
Methodist Cardiovascular Consultants - Dallas

Dallas, Texas, 75203, United States
Peking Union Medical College Hospital

Beijing, Beijing Municipality, 100730, China
Peking University First Hospital

Beijing, Beijing Municipality, 100034, China
Renji Hospital Shanghai Jiaotong University School of Medicine

Shanghai, Shanghai Municipality, 200001, China
The First Affiliated Hospital of Zhengzhou University

Zhengzhou, Henan, 450052, China
The Second Hospital of Anhui Medical University

Hefei, Anhui, 230601, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.